FMOC-3-(3-噻吩基)-DL-丙氨酸 | 678991-94-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 芴
• 中文名称: FMOC-3-(3-噻吩基)-DL-丙氨酸
• 英文名称: FMOC-DL-3-thienylalanine
• 英文别名: 2-(9H-fluoren-9-ylmethoxycarbonylamino)-3-thiophen-3-ylpropanoic acid
• CAS: 678991-94-1
• 化学式: C₂₂H₁₉NO₄S
• 分子量: 393.463
• InChiKey: LSBZJMRHROCYGY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  28
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  104
• 氢给体数：
  2
• 氢受体数：
  5

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2934999090

反应信息

• 作为反应物：
  描述：

  对氯苯甲酸 、 6-amino-5-(2-benzyloxy-2-methyl-propionylamino)-1-(3,4-dimethoxybenzyl)-2-thiouracil 、 FMOC-3-(3-噻吩基)-DL-丙氨酸 、 2-(9H-fluoren-9-ylmethoxycarbonyl)cyclohexane-1-carboxylic acid 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 4-二甲氨基吡啶 、 伯吉斯试剂 、 2-氯-1-甲基乙基(二甲基)胺盐酸盐 、 三氟乙酸 作用下， 以 1-methyl-2-pyrrolidinone (NMP) 为溶剂， 以92%的产率得到4-chloro-N-[2-({[(1S)-1-cyano-2-thien-3-ylethyl]amino}carbonyl)cyclohexyl]benzamide
  参考文献：
  名称：

  Benzamide nitriles

  摘要：

  式（I）的化合物 其中m，n，A，R1，R2，R3，R4，R5和R6如本文所述，以及制备这些化合物的方法以及利用这些化合物治疗由Cathepsin K介导的疾病或症状。

  公开号：

  US20040248949A1
• 作为产物：
  描述：

  3-(3-噻吩基)-DL-丙氨酸 、 9-芴甲基-N-琥珀酰亚胺基碳酸酯 在 phosphate buffer 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 24.0h， 生成 FMOC-3-(3-噻吩基)-DL-丙氨酸
  参考文献：
  名称：

  Novel Selective Inhibitors of the Interaction of Individual Nuclear Hormone Receptors with a Mutually Shared Steroid Receptor Coactivator 2

  摘要：

  Nuclear hormone receptor (NR) signaling, currently a therapeutic target in multiple diseases, involves an ordered series of protein interactions to regulate transcription in response to changing hormone levels. Later steps in the process of ligand-dependent signaling are driven by a highly conserved interaction between the NRs and the steroid receptor coactivators (SRCs) that is effected by a conserved interaction motif (L1XXL2L3), known as an NR box. Using computational design and combinatorial chemistry, we have produced novel alpha-helical proteomimetics of the second NR box of SRC2 that exploit structural differences between human estrogen receptor alpha (hERalpha), human estrogen receptor beta (hERbeta), and human thyroid hormone receptor beta (hTRbeta). The resulting library sequentially replaced each leucine with non-natural side chains. Screening this library using a quantitative competition assay revealed compounds that selectively inhibit the interaction of SRC2-2 with each individual NR in preference to its interaction with the other NR. This approach generated highly selective compounds from one that had no specificity for a particular family member. These compounds represent the first family-member-selective competitive inhibitors of the protein interactions of transcription factors.

  DOI：

  10.1021/ja0348391

文献信息

• Identification of Compounds Modifying A Cellular Response
  申请人：Thastrup Ole

  公开号：US20090239755A1

  公开（公告）日：2009-09-24

  The present invention relates to methods for identifying compounds capable of modulating a cellular response. The methods involve attaching living cells to solid supports comprising a library of test compounds. The test compounds are linked to the solid support via cleavable linkers and may thus be released from the solid supports. Solid supports comprising cells, wherein the cellular response of interest has been modulated are selected and the test compound of the solid support can then be identified. The cellular response may for example be changes in complex formation between proteins.

  本发明涉及识别能够调节细胞反应的化合物的方法。该方法涉及将活细胞附着在包含测试化合物库的固体支撑体上。测试化合物通过可切割的连接剂与固体支撑体连接，因此可以从固体支撑体释放出来。选择细胞被固体支撑体调节了感兴趣的细胞反应的固体支撑体，并且可以鉴定固体支撑体上的测试化合物。细胞反应可以是蛋白质复合物形成的变化，例如。
• MACROCYCLIC COMPOUNDS FOR INHIBITION OF TUMOR NECROSIS FACTOR ALPHA
  申请人：Lee Jinbo

  公开号：US20100152099A1

  公开（公告）日：2010-06-17

  The invention provides macrocyclic compounds and methods for their synthesis and use. In particular, the invention provides macrocyclic compounds that modulate the activity of tumor necrosis factor alpha and/or are useful in the treatment of medical conditions, such as, rheumatoid arthritis, psoriasis, and asthma.

  该发明提供了大环化合物及其合成和使用方法。具体而言，该发明提供了调节肿瘤坏死因子α活性和/或用于治疗医学状况（如类风湿性关节炎、银屑病和哮喘）的大环化合物。
• IDENTIFICATION OF COMPOUNDS MODIFYING A CELLULAR RESPONSE
  申请人：Thastrup Ole

  公开号：US20130123140A1

  公开（公告）日：2013-05-16

  The present invention relates to methods for identifying compounds capable of modulating a cellular response. The methods involve attaching living cells to solid supports comprising a library of test compounds. The test compounds are linked to the solid support via cleavable linkers and may thus be released from the solid supports. Solid supports comprising cells, wherein the cellular response of interest has been modulated are selected and the test compound of the solid support can then be identified. The cellular response may for example be changes in complex formation between proteins.

  本发明涉及识别能够调节细胞响应的化合物的方法。该方法包括将活细胞附着在包含一系列测试化合物的固体支持物上。测试化合物通过可切断的连接物与固体支持物相连，因此可以从固体支持物中释放出来。选择细胞响应已被调节的固体支持物，并可以鉴定固体支持物中的测试化合物。例如，细胞响应可以是蛋白质之间复合物形成的变化。
• US8338565B2
  申请人：——

  公开号：US8338565B2

  公开（公告）日：2012-12-25
• US9150899B2
  申请人：——

  公开号：US9150899B2

  公开（公告）日：2015-10-06